136 related articles for article (PubMed ID: 12168103)
1. The pattern of estradiol and progesterone differs in serum and tissue of benign and malignant ovarian tumors.
Lindgren PR; Bäckström T; Cajander S; Damber MG; Mählck CG; Zhu D; Olofsson JI
Int J Oncol; 2002 Sep; 21(3):583-9. PubMed ID: 12168103
[TBL] [Abstract][Full Text] [Related]
2. Changes in insulin-like growth factor I, 17-b-estradiol, and progesterone in postmenopausal women with benign and malignant ovarian tumours.
Waksmański B; Dudkiewicz J; Kowalski T
Med Sci Monit; 2001; 7(5):919-23. PubMed ID: 11535935
[TBL] [Abstract][Full Text] [Related]
3. Steroid production in different parts of malignant and benign ovarian tumors in vitro.
Ridderheim M; Mählck CG; Selstam G; Stendahl U; Bäckström T
Cancer Res; 1993 May; 53(10 Suppl):2309-12. PubMed ID: 8485717
[TBL] [Abstract][Full Text] [Related]
4. GnRH-II mRNA expression in tumor tissue and peripheral blood mononuclear cells (PBMCs) in patients with malignant and benign ovarian tumors.
Serin IS; Tanriverdi F; Ata CD; Akalin H; Ozcelik B; Ozkul Y; Kelestimur F
Eur J Obstet Gynecol Reprod Biol; 2010 Mar; 149(1):92-6. PubMed ID: 20018426
[TBL] [Abstract][Full Text] [Related]
5. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
[TBL] [Abstract][Full Text] [Related]
6. Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women.
Serin IS; Tanriverdi F; Yilmaz MO; Ozcelik B; Unluhizarci K
Gynecol Endocrinol; 2008 Mar; 24(3):117-21. PubMed ID: 18335323
[TBL] [Abstract][Full Text] [Related]
7. Fas and Fas ligand in cyst fluids, serum and tumors of patients with benign and (borderline) malignant ovarian tumors.
Arts HJ; de Jong S; Hollema H; Ten Hoor KA; de Vries EG; van der Zee AG
Int J Oncol; 2005 Feb; 26(2):379-84. PubMed ID: 15645122
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors.
Artini PG; Ruggiero M; Monteleone P; Carpi A; Cristello F; Cela V; Genazzani AR
Biomed Pharmacother; 2008; 62(6):373-7. PubMed ID: 18037256
[TBL] [Abstract][Full Text] [Related]
9. Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors.
Nowak M; Glowacka E; Szpakowski M; Szyllo K; Malinowski A; Kulig A; Tchorzewski H; Wilczynski J
Neuro Endocrinol Lett; 2010; 31(3):375-83. PubMed ID: 20588232
[TBL] [Abstract][Full Text] [Related]
10. Steroid hormones in ovarian vein and cyst fluid of a virilizing stromal tumor.
Muechler EK; Grove S; Kohler D
Obstet Gynecol; 1978 Nov; 52(5):609-12. PubMed ID: 214729
[TBL] [Abstract][Full Text] [Related]
11. Peritoneal fluid and HCG influence on steroid production from ovarian tumor tissue, in vitro.
Ridderheim M; Mählck CG; Selstam G; Stendahl U; Bäckström T
Anticancer Res; 1994; 14(5A):1753-8. PubMed ID: 7531411
[TBL] [Abstract][Full Text] [Related]
12. Gonadotropins and female sex steroid hormones in cyst fluid and serum from patients with ovarian tumors.
Thomas CM; Boss EA; Boonstra H; van Tienoven D; Sweep CG; Massuger LF
Eur J Gynaecol Oncol; 2008; 29(5):468-72. PubMed ID: 19051814
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
[TBL] [Abstract][Full Text] [Related]
14. Gonadotropin (LH, FSH) levels in serum and cyst fluid in epithelial tumors of the ovary.
Chudecka-Głaz A; Rzepka-Górska I; Kosmowska B
Arch Gynecol Obstet; 2004 Nov; 270(3):151-6. PubMed ID: 12883823
[TBL] [Abstract][Full Text] [Related]
15. Detailed morphology of human ovarian surface epithelium focusing on its metaplastic and neoplastic capability.
Okamura H; Katabuchi H
Ital J Anat Embryol; 2001; 106(2 Suppl 2):263-76. PubMed ID: 11732586
[TBL] [Abstract][Full Text] [Related]
16. Ovarian lipoid cell tumor. Steroid hormones and ultrastructure.
Muechler EK; Gillette MB; Cary D; Ryan CK; di Sant' Agnese PA; Markham RE; Jacobs LS
Diagn Gynecol Obstet; 1982; 4(4):309-15. PubMed ID: 7166118
[TBL] [Abstract][Full Text] [Related]
17. Progesterone and estradiol stimulate release of epidermal growth factor/transforming growth factor alpha by ovarian tumours in vitro.
Ridderheim M; Stendahl U; Bäckström T
Anticancer Res; 1994; 14(6B):2763-8. PubMed ID: 7872715
[TBL] [Abstract][Full Text] [Related]
18. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women.
Eliassen AH; Missmer SA; Tworoger SS; Spiegelman D; Barbieri RL; Dowsett M; Hankinson SE
J Natl Cancer Inst; 2006 Oct; 98(19):1406-15. PubMed ID: 17018787
[TBL] [Abstract][Full Text] [Related]
19. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D
J BUON; 2007; 12(1):99-104. PubMed ID: 17436409
[TBL] [Abstract][Full Text] [Related]
20. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity.
Bar JK; Grelewski P; Popiela A; Noga L; Rabczyñski J
Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
